- Report
- January 2026
- 198 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
- 376 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 180 Pages
Global
From €3906EUR$4,500USD£3,387GBP
- Report
- March 2025
- 145 Pages
Global
From €3471EUR$3,999USD£3,009GBP
- Report
- April 2025
- 100 Pages
Global
From €5165EUR$5,950USD£4,478GBP
- Report
- May 2025
- 200 Pages
Global
From €2161EUR$2,490USD£1,874GBP
- Report
- January 2026
- 181 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
- 184 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- August 2025
- 186 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- August 2025
- 182 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
- 189 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- September 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- July 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- April 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- April 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- April 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- April 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- April 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- March 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- May 2025
- 106 Pages
Global
From €4123EUR$4,750USD£3,575GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more